Kintor Starts Taiwan Trial of ALK-1 Antibody in HCC Patients
publication date: Nov 3, 2021
Suzhou Kintor Pharma has begun a Phase Ib/II trial of its ALK-1 antibody in combination with Alphamab's PD-L1/CTLA-4 bispecific antibody. The Taiwan trial will enroll patients with solid tumors, especially hepatocellular carcinoma (HCC). The study will focus on the safety, tolerability, pharmacokinetics and antitumor activity of the ALK-1 antibody, a potential first-in-class antibody that inhibits ALK-1/TGF-β signal transduction and tumor angiogenesis. In 2018, Kintor acquired global rights to the ALK-1 antibody from Pfizer. More details....
Stock Symbols: (HK: 9939) (NYSE: PFE)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.